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Brief CommuniCations
Preeclampsia is a complication of pregnancy characterized 
by novel onset of hypertension after 20 weeks gestation, 
accompanied by proteinuria. It affects 3%–8% of pregnan-
cies in the Western world and is a major cause of morbid-
ity and mortality for both mother and child.1,2 Although 
the exact biological mechanism of preeclampsia remains 
unclear, it is generally accepted to be the result of a combi-
nation of endothelial dysfunction, excessive inflammation 
beyond that of normal pregnancy and placental insuffi-
ciency.3 There is evidence of genetic susceptibility to the 
condition, as women with a maternal history of preec-
lampsia are at a 2- to 5-fold increased risk of develop-
ing preeclampsia themselves.3 Additionally, women who 
develop preeclampsia are at a significantly increased risk 
of future cardiovascular disease, including hypertension 
and stroke.4,5 Chronic hypertension is an established risk 
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BACKGROUND
Preeclampsia is a hypertensive complication of pregnancy character-
ized by novel onset of hypertension after 20 weeks gestation, accom-
panied by proteinuria. Epidemiological evidence suggests that genetic 
susceptibility exists for preeclampsia; however, whether preeclampsia 
is the result of underlying genetic risk for essential hypertension has 
yet to be investigated. Based on the hypertensive state that is charac-
teristic of preeclampsia, we aimed to determine if established genetic 
risk scores (GRSs) for hypertension and blood pressure are associated 
with preeclampsia.
METHODS
Subjects consisted of 162 preeclamptic cases and 108 normotensive 
pregnant controls, all of Iowa residence. Subjects’ DNA was extracted 
from buccal swab samples and genotyped on the Affymetrix Genome-
wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA). Missing 
genotypes were imputed using MaCH and Minimac software. GRSs 
were calculated for hypertension, systolic blood pressure (SBP), dias-
tolic blood pressure (DBP), and mean arterial pressure (MAP) using 
established genetic risk loci for each outcome. Regression analyses 
were performed to determine the association between GRS and risk 
of preeclampsia. These analyses were replicated in an independent US 
population of 516 cases and 1,097 controls of European ancestry.
RESULTS
GRSs for hypertension, SBP, DBP, and MAP were not significantly associ-
ated with risk for preeclampsia (P > 0.189). The results of the replication 
analysis also yielded nonsignificant associations.
CONCLUSIONS
GRSs for hypertension and blood pressure are not associated with 
preeclampsia, suggesting that an underlying predisposition to essen-
tial hypertension is not on the causal pathway of preeclampsia.
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factor for preeclampsia, although the onset of preeclampsia 
on a background of existing hypertension is referred to as 
superimposed preeclampsia.1,2 First trimester systolic blood 
pressure (SBP), diastolic blood pressure (DBP), and mean 
arterial pressure (MAP) are significantly elevated in women 
who go on to develop preeclampsia compared to those with 
normotensive pregnancies.6,7 These consistent phenom-
ena led us to question whether underlying genetic risks for 
essential hypertension or higher first trimester blood pres-
sure are predictors of the manifestation of preeclampsia.
The role of genetics in determining blood pressure has 
become clearer through genome-wide association studies 
(GWASs). The use of a genetic risk score (GRS) based on 
GWAS findings as an indicator of risk for a given condition 
is a novel method of investigating genetic susceptibility to a 
complex trait. These GRSs may be investigated for associa-
tion with an intermediate phenotype, such as blood pressure, 
which may then be investigated for association with risk for 
a disease outcome8,9 and vice versa.10 Specifically, one study 
constructed a GRS for hypertension based on a meta-anal-
ysis of GWAS-identified single nucleotide polymorphisms 
(SNPs) and its association with ischemic stroke,9,11 while 
another investigated a GRS for coronary artery disease and 
its association with hypertension.10
As preeclampsia is considered a hypertensive disorder 
of pregnancy and there is evidence of genetic susceptibil-
ity to the condition, including variants in vasoactive genes, 
it stands to reason that underlying genetic susceptibility to 
essential hypertension or higher first trimester blood pres-
sure may contribute to the manifestation of preeclampsia. In 
this study, we investigate the association between an estab-
lished GRS for essential hypertension and blood pressure 
and the outcome of preeclampsia in 2 different study popu-
lations. We hypothesize that women with higher genetic risk 
for elevated blood pressure and/or essential hypertension 
will be at increased risk of preeclampsia. To our knowledge, 
this is the first study to use GRS for essential hypertension 
and blood pressure in relation to preeclampsia.
METHODS
Study population
This study involved subjects from the Study of Pregnancy 
Hypertension in Iowa (SOPHIA) case–control population. 
The SOPHIA population is composed of nulliparous residents 
of 42 Iowa counties who had a live birth from August 2002 
through April 2005. Two hundred seventy subjects, including 
162 cases and 108 controls, were used in GRS analyses.
A replication population consisting of 516 preeclampsia 
cases and 1,097 normotensive controls of European ancestry 
was aggregated from 5 US sites. These sites were Institutional 
Review Board–approved hospital and internet-based collec-
tions and subjects were matched to population controls.
Phenotype definition
The methods for classifying preeclampsia in the SOPHIA 
study have been described previously.12–14 Cases were ini-
tially selected based on an indication of “pregnancy-induced 
hypertension” or “eclampsia” on birth certificate records. 
Randomly selected control subjects had no record of hyper-
tension on birth certificate records and were frequency 
matched to cases based on county of residence. Potential 
subjects were excluded for chronic hypertension, age <18 at 
delivery, non-English speaking, history of autoimmune dis-
ease, recurrent spontaneous abortion, multiple gestations, 
major congenital anomalies, infant death, or seriously ill 
infant.14 Medical records were abstracted from the antenatal, 
intrapartum, and postpartum periods to identify all blood 
pressure and urinary protein measurements before, during, 
and after pregnancy; this information was used to classify 
patients with preeclampsia, gestational hypertension, or as 
normotensive controls. Preeclampsia was defined accord-
ing to National Heart, Lung, and Blood Institute guidelines: 
(i) sustained de novo hypertension (≥140 mm Hg systolic or 
≥90 mm Hg diastolic on ≥2 occasions at least 6 hours apart) 
beginning no earlier than 20 weeks gestation and (ii) pro-
teinuria, defined as urinary protein concentrations ≥30 mg/
dL (equivalent to a dipstick value of 1+ from ≥2 specimens 
≥4 hours apart or a 24-hour urine collection with ≥300 mg of 
protein).15 Gestational hypertension was defined as de novo 
hypertension in the absence of proteinuria and preeclampsia 
as gestational hypertension with proteinuria. Normotensive 
controls consisted of women with no evidence of hyperten-
sion or proteinuria during their pregnancy.
In the replication population, preeclampsia was defined 
according to the same National Heart, Lung, and Blood 
Institute guidelines as the SOPHIA population. Boston and 
USC samples also included superimposed preeclampsia in 
their case definition. Normotensive controls consisted of 
pregnant women with no history of chronic hypertension 
and no evidence of hypertensive disorders of pregnancy or 
proteinuria.
Genotyping
DNA collection, extraction, and genotyping methods for 
this study have been described previously.14 A subset of sam-
ples (N  =  270) from the SOPHIA study underwent GWA 
analysis based on Caucasian race and consent for future 
research. Genotyping was performed at the Rockefeller 
University Genomics Resource Center using Affymetrix 
Genome-wide Human SNP Array 6.0 (Affymetrix, Santa 
Clara, CA). Samples with a call rate less than 86% were 
excluded (n = 1).14 The mean call rate among the remain-
ing subjects was 94.4%.14 SNPs on chromosomes 1–22 were 
imputed using MaCH software,16 using the 379 samples of 
European ancestry (CEPH) from the 1000 Genomes Project 
phase 1 as the reference panel.17 Haplotypes for the SOPHIA 
subjects were estimated using MaCH software, and impu-
tation was performed using Minimac software.18 All GRS 
SNPs were available in the SOPHIA population without 
requiring a proxy SNP.
DNA from the replication population was extracted from 
blood, saliva, or buccal samples according to standard pro-
cedures. Samples were genotyped on a cardiovascular gene-
centric 50 K SNP array.19 Genotypes were clustered using 
Illumina Beadstudio software and subjected to quality con-
trol filters at the sample and SNP level. Samples of European 
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ancestry were identified using principal component analysis 
using HapMap3 European (CEU), African (YRI), and Asian 
(JPT + CHB) panels as reference standards.20 SNPs were 
removed for genotyping efficiency <95%, departure from 
Hardy–Weinberg equilibrium (P < 10−6) in controls, differ-
ential missingness between cases and controls (P < 0.05), or 
batch effects (P < 10−6).14 The cardiovascular disease gene-
centric array contained a limited number of index SNPs 
for blood pressure measurements, so GRS analyses utilized 
proxy SNPs with the strongest correlation (pairwise r2 > 0.8) 
to the untyped index SNP in the 1KG CEU sample.
Statistical analyses
GRSs for hypertension, SBP, DBP, and MAP were con-
structed for each subject based on the beta coefficients of 
GWAS-significant variants with a source-reported P-value < 
1.0E-04.11,21 The number of source SNPs were 27, 28, 28, and 
23 for hypertension, SBP, DBP, and MAP, respectively. After 
imputation of the SOPHIA genotypes, the GRS for hyper-
tension consisted of 26 SNPs, the GRS for SBP and DBP con-
sisted of 27 SNPs, and the GRS for MAP consisted of 22 SNPs. 
SNPs and beta coefficients used to construct these GRS are 
reported in Supplementary Table 1. Specifically, GRSs were 
constructed based on the reported beta coefficient for the 
effect allele at the given SNP. Alleles were coded such that the 
reported beta coefficient would be a positive value; for SNPs 
where the source allele had a negative beta coefficient, the 
other allele was used and the beta coefficient was made posi-
tive. The beta coefficient of each effect allele was summed for 
each subject based on their genotypes, such that individuals 
homozygous for the noncoded allele would receive a value 
of 0 for that locus, heterozygous individuals would receive 
the value of the beta coefficient at that locus, and individu-
als homozygous for the coded allele would receive double 
the beta coefficient for that locus. Similar GRSs were con-
structed for the replication population. Due to the limited 
availability of index and proxy SNPs, the replication study 
used 6 SNPs for hypertension, SBP, and DBP, and 5 SNPs 
for MAP. SNPs and beta coefficients used to construct these 
GRS are reported in Supplementary Table 2.
Logistic regression was performed to assess the associa-
tion between the 4 GRSs and preeclampsia using Statistical 
Analysis Software version 9.3 (Cary, NC). Our primary 
analyses examined the relationship between each GRS, 
independently, and risk of preeclampsia. In a subset of our 
sample where first trimester blood pressure measurements 
were available (n = 131 cases, 87 controls), we examined the 
relationship between first trimester DBP, SBP, and MAP with 
risk for preeclampsia. In addition, we examined the relation-
ship between each GRS and its associated blood pressure 
measurement. First trimester MAP was calculated for each 
subject using the formula (MAP  =  diastolic + 1/3(systolic 
− diastolic)) based on subjects’ first trimester average SBP 
and DBP. Analyses involving the blood pressure measure-
ments for SBP, DBP, and MAP were performed unadjusted 
and adjusted for body mass index (BMI). Other covariates 
examined included maternal age at delivery, maternal edu-
cation level, smoking during the first trimester, and leisure 
time physical activity. Our replication population did not 
include any information on blood pressure measurements 
or information on maternal age, BMI, or smoking; therefore, 
these analyses were only examined in our primary popula-
tion. GRSs for SBP, DBP, and MAP were also broken into 
quartiles based on their distributions among control subjects 
and then assessed for their association with SBP, DBP, and 
MAP, respectively, using linear regression.
RESULTS
GRSs for hypertension, SBP, DBP, and MAP were not sig-
nificantly associated with preeclampsia. Additionally, quar-
tile analyses did not demonstrate a statistically significant 
trend for any of the GRSs (Table 1). Similar analyses in the 
replication population were also nonsignificant (Table 2).
To determine the effectiveness of each GRS in predicting 
its respective blood pressure measurement, GRSs for SBP, 
DBP, and MAP were analyzed against measured SBP, DBP, 
and MAP values, respectively, using linear regression. The 
GRS for DBP was significantly associated with DBP before 
and after adjustment for pre-pregnancy BMI and the GRS 
for SBP was marginally associated with SBP unadjusted 
(P = 0.07) and significantly associated after adjustment for 
pre-pregnancy BMI (P  <  0.05) (Supplementary Table  3). 
The GRS for MAP was not significantly associated with 
first trimester MAP. In the quartile analyses, tests for trend 
demonstrated a significant trend for the DBP GRS and 
measured DBP (P < 0.05), a marginally significant trend for 
the association between SBP GRS and SBP measurements 
(P = 0.11) and no trend between the MAP GRS and MAP 
(Supplementary Table 3).
First trimester SBP, DBP, and MAP were significantly 
associated with preeclampsia in a subset of the SOPHIA 
population (P < 0.0001), with increased first trimester blood 
pressures associated with increased risk of preeclampsia 
(Supplementary Table 4). These associations remained sig-
nificant after adjustment for BMI. All 3 trends were highly 
significant (P ≤ 0.0001).
DISCUSSION
Established GRSs for hypertension, SBP, DBP, and MAP 
were not associated with preeclampsia. This suggests that 
an alternative pathogenesis model is responsible for the 
relationship between first trimester blood pressure and 
risk for preeclamptic hypertension. In our primary study 
population, we demonstrate that first trimester SBP, DBP, 
and MAP measurements are significantly associated with 
preeclampsia. These results are consistent with existing 
knowledge.6,7,22,23 Furthermore, GRSs for SBP and DBP 
were significantly associated with first trimester SBP and 
DBP, respectively, after adjustment for pre-pregnancy BMI 
(P < 0.05), supporting that these GRSs are associated with 
blood pressure measurements in our cohort. Together, these 
data support the hypothesis that the increased risk of future 
cardiovascular disease, including hypertension and stroke, 
following a preeclamptic pregnancy is likely due to dam-
age done during pregnancy rather than underlying genetic 
risk for hypertension. These findings shed light on the dis-
puted pathophysiology of preeclampsia. Although chronic 
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hypertension is a risk factor for preeclampsia,2 our findings 
suggest that genetic susceptibility for hypertension is not a 
necessary causal factor in the development of preeclampsia.
It is important to note that blood pressure is only one aspect 
of the pathophysiology of preeclampsia. Meta-analyses of 
the genetics of preeclampsia have identified several biologi-
cal processes associated with risk for preeclampsia repre-
sented by only a handful of promising candidate genes.24,25 
Although genes involved with vasoactive processes have 
been implicated in the pathophysiology of preeclampsia, a 
recent meta-analysis found genes associated with thrombo-
philia to be more strongly associated with preeclampsia.24 
Another important contributor to the etiology of preec-
lampsia includes endothelial dysfunction, including insuf-
ficient spiral artery invasion and inappropriate endothelial 
cell activation,26 which may be mediated by dyslipidemia.27 
Epidemiologic studies and GWASs, by our group and oth-
ers, support the role of dyslipidemia in preeclampsia. This 
includes elevated triglycerides throughout pregnancy and 
decreased high density lipoprotein cholesterol in the third 
trimester.28,29 Of interest, the lipoprotein lipase gene, LPL, is 
associated with both preeclampsia and cardiovascular dis-
ease.25 We have previously reported an association between 
a GRS for decreased levels of high density lipoprotein cho-
lesterol, which included a variant in LPL, and increased risk 
for preeclampsia.8 Thus, the etiology of preeclampsia likely 
encompasses a myriad of factors on its causal pathway, and 
our current data, which are supported by other genetic stud-
ies, suggest that genes involved in the vasoactive process 
including those that predict blood pressure are not primary 
candidates on the causal pathway of preeclampsia.
A significant strength of our study was the availability of 
blood pressure values in addition to the rigorous assessment 
of preeclampsia status in our primary study population. The 
availability of first trimester blood pressure measurements 
allowed us to assess the relationship between first trimester 
blood pressure and preeclampsia and to evaluate the associa-
tion between GRSs for SBP, DBP, and MAP and their respec-
tive first trimester blood pressure measurements. Although 
we were able to include maternal blood pressure measure-
ments in our study, we lack blood pressure measurements 
prior to conception. Thus, although we excluded women 
with preexisting chronic hypertension, we cannot determine 
if subjects with preeclampsia had higher blood pressure 
while still being within the normotensive range prior to con-
ception. An additional limitation is the lack of a standard-
ized protocol for measuring blood pressure, given the nature 
of a retrospective case–control study design.
It is important to note that the SNPs involved in this 
study only explain a small fraction of the heritable varia-
tion in blood pressure (<3%); however, this was also the case 
in the meta-analysis of GWAS from which the SNPs came 
(~2.2%).11 Furthermore, in our replication, we were only 
able to include a fraction of the SNPs in the initial GRS, and 
therefore, replication in other populations is warranted. As 
additional SNPs influencing blood pressure are identified 
and the genetic risk factors for hypertension and blood pres-
sure are better understood, it will be important to reexamine 
the relationship between preeclampsia and the genetic risk 
for hypertension.
The SNPs used to generate GRS for this study were based on 
the results of the meta-analysis of multiple GWASs of hyper-
tension and blood pressure–associated loci, demonstrating 
the reliability of these SNPs in their association with hyperten-
sion and blood pressure.11,21 Further, most of these same SNPs 
were used in another GRS study of hypertension and ischemic 
stroke, demonstrating a precedent for the use of a GRS for 
blood pressure and its association with a disease outcome.9 
However, given that all of these studies were in a population 
of European ancestry and our study population is primarily 
Caucasian, it is necessary to evaluate these variants in other 
populations to determine their association with blood pres-
sure in other racial and ethnic groups. Although our primary 
study population was relatively small, the fact that we find that 
(i) the GRSs of SBP and DBP are associated with their respec-
tive first trimester measurement, (ii) first trimester blood 
pressure measurements are associated with preeclampsia, and 
(iii) the results of nonsignificant associations between each 
GRS and preeclampsia were also observed in our replication 
population strengthens the conclusions of our study.
Our study suggests that elevated first trimester blood pres-
sures are likely the result of early pathological changes of 
preeclampsia, rather than primary causal factors. Based on our 
findings, we propose that the hypertension present in preec-
lampsia is of a different etiology from essential hypertension. 
Our replication of the well-established association between 
elevated first trimester blood pressure and subsequent preec-
lampsia further supports our conclusion that this increase 
in blood pressure represents early pathological changes that 
eventually manifest as preeclampsia. Thus, since an estab-
lished risk score for blood pressure was not associated with 
the development of preeclampsia and none of our subjects 
had a history of hypertension prior to conception, we can con-
clude that the hypertension present in preeclampsia is not due 
to a risk for chronic or “essential” hypertension but rather the 
early etiology of preeclampsia. Our previous genetic and epi-
demiologic studies suggest that other pathways such as dyslip-
idemia may play a causal role in preeclampsia. Given that the 
origins of preeclampsia are still not well understood, future 
research is needed on the etiology of preeclampsia in order to 
explain the origin of this early increase in blood pressure in 
pregnant subjects who go on to be diagnosed with preeclamp-
sia. Although the complex pathophysiology of preeclamp-
sia remains unclear, the results of our study suggest that the 
hypertensive state that is characteristic of preeclampsia is not 
due to genetic susceptibility for essential hypertension.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal 
of Hypertension (http://ajh.oxfordjournals.org).
ACKNOWLEDGMENTS
The SOPHIA study was supported by the National 
Institute of Child Health and Human Development, 
National Institutes of Health (R01 HD32579), and the Verto 
American Journal of Hypertension 29(1) January 2016 23
Genetic Risk Score Hypertension and Preeclampsia
Institute. The replication study was funded in part by a 
Gertie Marx Grant from the Society for Obstetric Anesthesia 
and Perinatology. We acknowledge contribution of samples 
for IBC array genotyping by preeclampsia investigators 
from Boston (B. Bateman and S.A. Karumanchi), Iowa (J. 
Murray), USC (M.L. Wilson), and Yale (E. Norwitz) as well 
as contribution of genotype data from the preeclampsia 
CARe IBC study.30
DISCLOSURE
The authors declared no conflict of interest.
REFERENCES
 1. Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi JM. Pre-eclampsia: 
pathophysiology, diagnosis, and management. Vasc Health Risk Manage 
2011; 7:467–474.
 2. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 
365:785–799.
 3. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive mater-
nal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 
180:499–506.
 4. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and 
risk of cardiovascular disease and cancer in later life: systematic review 
and meta-analysis. BMJ 2007; 335:974.
 5. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, 
Hannaford P, Smith WC. Hypertensive diseases of pregnancy and risk 
of hypertension and stroke in later life: results from cohort study. BMJ 
2003; 326:845.
 6. Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, 
Thorp JM Jr, Mercer BM, Peaceman AM, Ramin SM, Carpenter 
MW, Iams JD, Sciscione A, Harper M, Tolosa JE, Saade G, Sorokin 
Y, Anderson GD; Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD) Maternal-Fetal Medicine 
Units (MFMU) Network. First-trimester prediction of preeclampsia in 
nulliparous women at low risk. Obstet Gynecol 2012; 119:1234–1242.
 7. Miller RS, Rudra CB, Williams MA. First-trimester mean arterial pres-
sure and risk of preeclampsia. Am J Hypertens 2007; 20:573–578.
 8. Spracklen CN, Saftlas AF, Triche EW, Bjonnes A, Keating B, Saxena R, 
Breheny PJ, Dewan AT, Robinson JG, Hoh J, Ryckman KK. Genetic pre-
disposition to dyslipidemia and risk of preeclampsia. Am J Hypertens 
2014.
 9. Fava C, Sjogren M, Olsson S, Lovkvist H, Jood K, Engstrom G, Hedblad 
B, Norrving B, Jern C, Lindgren A, Melander O. A genetic risk score for 
hypertension associates with the risk of ischemic stroke in a Swedish 
case-control study. Eur J Hum Genet 2014.
 10. Fujimaki T, Oguri M, Horibe H, Kato K, Matsuoka R, Abe S, Tokoro F, 
Arai M, Noda T, Watanabe S, Yamada Y. Association of a transcription 
factor 21 gene polymorphism with hypertension. Biomed Rep 2015; 
3:118–122.
 11. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, 
Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, 
O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer 
L, Zhao JH, Aulchenko Y, Heath S, Sõber S, Parsa A, Luan J, Arora P, 
Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka 
T, Wild SH, Rudan I, Igl W, Milaneschi Y, Parker AN, Fava C, Chambers 
JC, Fox ER, Kumari M, Go MJ, van der Harst P, Kao WH, Sjögren M, 
Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, 
Liu Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD, 
Lehtimäki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper 
MN, Platou CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund 
PS, Kuznetsova T, Uiterwaal CS, Adeyemo A, Palmas W, Campbell H, 
Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND, Aspelund T, Garcia 
M, Chang YP, O'Connell JR, Steinle NI, Grobbee DE, Arking DE, 
Kardia SL, Morrison AC, Hernandez D, Najjar S, McArdle WL, Hadley 
D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby 
JP, Lawrence RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li 
Y, Young JH, Bis JC, Kähönen M, Viikari J, Adair LS, Lee NR, Chen 
MH, Olden M, Pattaro C, Bolton JA, Köttgen A, Bergmann S, Mooser 
V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J, Kulkarni 
SR, Bornstein SR, Grässler J, Groop L, Voight BF, Kettunen J, Howard P, 
Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw 
KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins FS, Bonnycastle 
LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand 
SM, Staessen JA, Wang TJ, Burton PR, Soler Artigas M, Dong Y, Snieder 
H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, 
Wiggins KL, Doumatey A, Shriner D, Veldre G, Viigimaa M, Kinra S, 
Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle DS, 
Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, 
Iwai N, Kita Y, Ogihara T, Ohkubo T, Okamura T, Ueshima H, Umemura 
S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee 
JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong 
A, Narisu N, Stančáková A, Raffel LJ, Yao J, Kathiresan S, O'Donnell 
CJ, Schwartz SM, Ikram MA, Longstreth WT Jr, Mosley TH, Seshadri 
S, Shrine NR, Wain LV, Morken MA, Swift AJ, Laitinen J, Prokopenko 
I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel A, 
Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani 
KR, Yajnik CS, Hofman A, Mattace-Raso FU, Oostra BA, Demirkan A, 
Isaacs A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela 
M, Kangas AJ, Lyytikäinen LP, Soininen P, Tukiainen T, Würtz P, Ong 
RT, Dörr M, Kroemer HK, Völker U, Völzke H, Galan P, Hercberg S, 
Lathrop M, Zelenika D, Deloukas P, Mangino M, Spector TD, Zhai 
G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar MV, Denniff M, 
Zukowska-Szczechowska E, Wagenknecht LE, Fowkes FG, Charchar FJ, 
Schwarz PE, Hayward C, Guo X, Rotimi C, Bots ML, Brand E, Samani 
NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer 
LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, 
Ganesh SK, Wong TY, Tai ES, Cooper RS, Laakso M, Rao DC, Harris 
TB, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Miki T, 
Saleheen D, Chandak GR, Coresh J, Navis G, Salomaa V, Han BG, Zhu 
X, Kooner JS, Melander O, Ridker PM, Bandinelli S, Gyllensten UB, 
Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pramstaller 
PP, Elosua R, Soranzo N, Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner 
AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ, Gudnason 
V, Rotter JI, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen 
AL, Beckmann JS, Boerwinkle E, Vasan RS, Boehnke M, Larson MG, 
Järvelin MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott P, van Duijn 
CM, Newton-Cheh C, Levy D, Caulfield MJ, Johnson T; International 
Consortium for Blood Pressure Genome-Wide Association Studies; 
CARDIoGRAM Consortium; CKDGen Consortium; KidneyGen 
Consortium; EchoGen Consortium; CHARGE-HF Consortium. 
Genetic variants in novel pathways influence blood pressure and car-
diovascular disease risk. Nature 2011; 478:103–109.
 12. Saftlas AF, Rubenstein L, Prater K, Harland KK, Field E, Triche EW. 
Cumulative exposure to paternal seminal fluid prior to concep-
tion and subsequent risk of preeclampsia. J Reprod Immunol 2014; 
101–102:104–110.
 13. Triche EW, Harland KK, Field EH, Rubenstein LM, Saftlas AF. 
Maternal-fetal HLA sharing and preeclampsia: variation in effects by 
seminal fluid exposure in a case-control study of nulliparous women in 
Iowa. J Reprod Immunol 2014; 101–102:111–119.
 14. Zhao L, Triche EW, Walsh KM, Bracken MB, Saftlas AF, Hoh J, Dewan 
AT. Genome-wide association study identifies a maternal copy-num-
ber deletion in PSG11 enriched among preeclampsia patients. BMC 
Pregnancy Childbirth 2012; 12:61.
 15. Roberts JM, Pearson GD, Cutler JA, Lindheimer MD; National Heart 
Lung and Blood Institute. Summary of the NHLBI working group on 
research on hypertension during pregnancy. Hypertens Pregnancy 2003; 
22:109–127.
 16. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence 
and genotype data to estimate haplotypes and unobserved genotypes. 
Genet Epidemiol 2010; 34:816–834.
 17. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks 
LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, 
McVean GA. An integrated map of genetic variation from 1,092 human 
genomes. Nature 2012; 491:56–65.
 18. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast 
and accurate genotype imputation in genome-wide association studies 
through pre-phasing. Nat Genet 2012; 44:955–959.
24 American Journal of Hypertension 29(1) January 2016
Smith et al.
 19. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, 
Galver L, Barrett JC, Grant SF, Farlow DN, Chandrupatla HR, Hansen 
M, Ajmal S, Papanicolaou GJ, Guo Y, Li M, Derohannessian S, de Bakker 
PI, Bailey SD, Montpetit A, Edmondson AC, Taylor K, Gai X, Wang SS, 
Fornage M, Shaikh T, Groop L, Boehnke M, Hall AS, Hattersley AT, 
Frackelton E, Patterson N, Chiang CW, Kim CE, Fabsitz RR, Ouwehand 
W, Price AL, Munroe P, Caulfield M, Drake T, Boerwinkle E, Reich D, 
Whitehead AS, Cappola TP, Samani NJ, Lusis AJ, Schadt E, Wilson JG, 
Koenig W, McCarthy MI, Kathiresan S, Gabriel SB, Hakonarson H, 
Anand SS, Reilly M, Engert JC, Nickerson DA, Rader DJ, Hirschhorn 
JN, Fitzgerald GA. Concept, design and implementation of a cardiovas-
cular gene-centric 50 k SNP array for large-scale genomic association 
studies. PLoS One 2008; 3:e3583.
 20. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, 
Peltonen L, Dermitzakis E, Schaffner SF, Yu F, Peltonen L, Dermitzakis 
E, Bonnen PE, Altshuler DM, Gibbs RA, de Bakker PI, Deloukas P, 
Gabriel SB, Gwilliam R, Hunt S, Inouye M, Jia X, Palotie A, Parkin 
M, Whittaker P, Yu F, Chang K, Hawes A, Lewis LR, Ren Y, Wheeler 
D, Gibbs RA, Muzny DM, Barnes C, Darvishi K, Hurles M, Korn JM, 
Kristiansson K, Lee C, McCarrol SA, Nemesh J, Dermitzakis E, Keinan 
A, Montgomery SB, Pollack S, Price AL, Soranzo N, Bonnen PE, Gibbs 
RA, Gonzaga-Jauregui C, Keinan A, Price AL, Yu F, Anttila V, Brodeur 
W, Daly MJ, Leslie S, McVean G, Moutsianas L, Nguyen H, Schaffner 
SF, Zhang Q, Ghori MJ, McGinnis R, McLaren W, Pollack S, Price AL, 
Schaffner SF, Takeuchi F, Grossman SR, Shlyakhter I, Hostetter EB, 
Sabeti PC, Adebamowo CA, Foster MW, Gordon DR, Licinio J, Manca 
MC, Marshall PA, Matsuda I, Ngare D, Wang VO, Reddy D, Rotimi CN, 
Royal CD, Sharp RR, Zeng C, Brooks LD, McEwen JE. Integrating com-
mon and rare genetic variation in diverse human populations. Nature 
2010; 467:52–58.
 21. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, 
Bochud M, Rice KM, Henneman P, Smith AV, Ehret GB, Amin N, 
Larson MG, Mooser V, Hadley D, Dörr M, Bis JC, Aspelund T, Esko T, 
Janssens AC, Zhao JH, Heath S, Laan M, Fu J, Pistis G, Luan J, Arora P, 
Lucas G, Pirastu N, Pichler I, Jackson AU, Webster RJ, Zhang F, Peden 
JF, Schmidt H, Tanaka T, Campbell H, Igl W, Milaneschi Y, Hottenga 
JJ, Vitart V, Chasman DI, Trompet S, Bragg-Gresham JL, Alizadeh BZ, 
Chambers JC, Guo X, Lehtimäki T, Kühnel B, Lopez LM, Polašek O, 
Boban M, Nelson CP, Morrison AC, Pihur V, Ganesh SK, Hofman A, 
Kundu S, Mattace-Raso FU, Rivadeneira F, Sijbrands EJ, Uitterlinden 
AG, Hwang SJ, Vasan RS, Wang TJ, Bergmann S, Vollenweider P, 
Waeber G, Laitinen J, Pouta A, Zitting P, McArdle WL, Kroemer HK, 
Völker U, Völzke H, Glazer NL, Taylor KD, Harris TB, Alavere H, Haller 
T, Keis A, Tammesoo ML, Aulchenko Y, Barroso I, Khaw KT, Galan P, 
Hercberg S, Lathrop M, Eyheramendy S, Org E, Sõber S, Lu X, Nolte 
IM, Penninx BW, Corre T, Masciullo C, Sala C, Groop L, Voight BF, 
Melander O, O'Donnell CJ, Salomaa V, d'Adamo AP, Fabretto A, Faletra 
F, Ulivi S, Del Greco F, Facheris M, Collins FS, Bergman RN, Beilby JP, 
Hung J, Musk AW, Mangino M, Shin SY, Soranzo N, Watkins H, Goel 
A, Hamsten A, Gider P, Loitfelder M, Zeginigg M, Hernandez D, Najjar 
SS, Navarro P, Wild SH, Corsi AM, Singleton A, de Geus EJ, Willemsen 
G, Parker AN, Rose LM, Buckley B, Stott D, Orru M, Uda M, van der 
Klauw MM, Zhang W, Li X, Scott J, Chen YD, Burke GL, Kähönen M, 
Viikari J, Döring A, Meitinger T, Davies G, Starr JM, Emilsson V, Plump 
A, Lindeman JH, Hoen PA, König IR, Felix JF, Clarke R, Hopewell JC, 
Ongen H, Breteler M, Debette S, Destefano AL, Fornage M, Mitchell 
GF, Smith NL, Holm H, Stefansson K, Thorleifsson G, Thorsteinsdottir 
U, Samani NJ, Preuss M, Rudan I, Hayward C, Deary IJ, Wichmann 
HE, Raitakari OT, Palmas W, Kooner JS, Stolk RP, Jukema JW, Wright 
AF, Boomsma DI, Bandinelli S, Gyllensten UB, Wilson JF, Ferrucci L, 
Schmidt R, Farrall M, Spector TD, Palmer LJ, Tuomilehto J, Pfeufer A, 
Gasparini P, Siscovick D, Altshuler D, Loos RJ, Toniolo D, Snieder H, 
Gieger C, Meneton P, Wareham NJ, Oostra BA, Metspalu A, Launer L, 
Rettig R, Strachan DP, Beckmann JS, Witteman JC, Erdmann J, van Dijk 
KW, Boerwinkle E, Boehnke M, Ridker PM, Jarvelin MR, Chakravarti 
A, Abecasis GR, Gudnason V, Newton-Cheh C, Levy D, Munroe PB, 
Psaty BM, Caulfield MJ, Rao DC, Tobin MD, Elliott P, van Duijn CM; 
LifeLines Cohort Study; EchoGen Consortium; AortaGen Consortium; 
CHARGE Consortium Heart Failure Working Group; KidneyGen 
Consortium; CKDGen Consortium; Cardiogenics Consortium; 
CardioGram. Genome-wide association study identifies six new loci 
influencing pulse pressure and mean arterial pressure. Nat Genet 2011; 
43:1005–1011.
 22. Kuc S. Maternal characteristics, mean arterial pressure and serum 
markers in early prediction of preeclampsia. PLoS One 2013; 
8:e63546
 23. Moutquin JM, Rainville C, Giroux L, Raynauld P, Amyot G, Bilodeau R, 
Pelland N. A prospective study of blood pressure in pregnancy: predic-
tion of preeclampsia. Am J Obstet Gynecol 1985; 151:191–196.
 24. Fong FM, Sahemey MK, Hamedi G, Eyitayo R, Yates D, Kuan V, 
Thangaratinam S, Walton RT. Maternal genotype and severe preec-
lampsia: a HuGE review. Am J Epidemiol 2014; 180:335–345.
 25. Buurma AJ, Turner RJ, Driessen JH, Mooyaart AL, Schoones JW, 
Bruijn JA, Bloemenkamp KW, Dekkers OM, Baelde HJ. Genetic vari-
ants in pre-eclampsia: a meta-analysis. Hum Reprod Update 2013; 
19:289–303.
 26. Szpera-Gozdziewicz A, Breborowicz GH. Endothelial dysfunction in 
the pathogenesis of pre-eclampsia. Front Biosci (Landmark Ed) 2014; 
19:734–746.
 27. Taylor R, Roberts J. Endothelial Cell Dysfunction, 3rd edn. Elsevier: San 
Diego, CA, 2009.
 28. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. 
Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. 
Am J Epidemiol 2014; 180:346–358.
 29. Gallos ID, Sivakumar K, Kilby MD, Coomarasamy A, Thangaratinam S, 
Vatish M. Pre-eclampsia is associated with, and preceded by, hypertri-
glyceridaemia: a meta-analysis. BJOG 2013; 120:1321–1332.
 30. Maric-Bilkan C, Symonds M, Ozanne S, Alexander BT. Impact of 
maternal obesity and diabetes on long-term health of the offspring. Exp 
Diabetes Res 2011; 2011:163438.
